* Cytek Biosciences Inc reported quarterly adjusted earnings of 1 cent per share for the quarter ended September 30, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of six analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -3 cents tozero cents per share.
* Revenue rose 7.3% to $51.50 million from a year ago; analysts expected $50.70 million.
* Cytek Biosciences Inc's reported EPS for the quarter was 1 cent.
* The company reported quarterly net income of $941 thousand.
* Cytek Biosciences Inc shares had fallen by 6.1% this quarter and lost 43.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 7.1% in the last three months.
* In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Cytek Biosciences Inc is $8.00 This summary was machine generated from LSEG data November 6 at 04:35 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.01 0.01 Beat
Jun. 30 2024 -0.03 -0.08 Missed
Mar. 31 2024 -0.04 -0.05 Missed
Dec. 31 2023 0.00 0.04 Beat
Comments